S.Res. 752

119 SRES 752 IS: Expressing support for the designation of the month of May 2026 as “Progressive Supranuclear Palsy and Corticobasal Degeneration Awareness Month”.
 U.S. Senate
 2026-05-21
 text/xml
 EN
 Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
 III  119th CONGRESS  2d Session  S. RES. 752  IN THE SENATE OF THE UNITED STATES   May 21, 2026   Mr. Blumenthal  submitted the following resolution; which was referred to the  Committee on Health, Education, Labor, and Pensions    RESOLUTION
Expressing support for the designation of the month of May 2026 as  Progressive Supranuclear Palsy and Corticobasal Degeneration Awareness Month .
Whereas progressive supranuclear palsy, often referred to as  PSP , and corticobasal degeneration, often referred to as  CBD , are rare, adult onset, rapidly progressing neurodegenerative disorders that affect multiple areas of the brain and cause complex symptoms and care needs;
Whereas, although some symptoms may appear similar to those of other neurological diagnoses like Parkinson’s disease and frontotemporal dementia, progressive supranuclear palsy and corticobasal degeneration are distinct diseases with their own unique trajectories and care needs;
Whereas, while estimates vary and the conditions are frequently misdiagnosed, approximately 30,000 Americans are living with progressive supranuclear palsy and 2,000 Americans are living with corticobasal degeneration;
Whereas delays in the accurate diagnosis of progressive supranuclear palsy and corticobasal degeneration and access to neurology professionals specialized in these diseases are common and cause confusion, anxiety, and frustration among patients;
Whereas progressive supranuclear palsy and corticobasal degeneration can cause significant difficulty with movement, balance, speech, swallowing, cognition, vision, mood, and a variety of other complex symptoms;
Whereas progressive supranuclear palsy and corticobasal degeneration are aggressive in their progression, with most individuals becoming dependent on care in 3 to 4 years and having an overall life expectancy of 7 to 8 years from symptom onset;
Whereas there are currently no disease-modifying treatments for progressive supranuclear palsy or corticobasal degeneration;
Whereas more research is needed to understand the roles of environmental factors and genetics in why people develop progressive supranuclear palsy and corticobasal degeneration;
Whereas there are countless family caregivers, friends, and loved ones whose lives are greatly affected by progressive supranuclear palsy and corticobasal degeneration;
Whereas additional research, support services, and education are needed to maintain quality of life for those affected by the disease, to develop better treatments and prevention of complications, and to find cures for progressive supranuclear palsy and corticobasal degeneration; and
Whereas the designation of the month of May 2026 as  Progressive Supranuclear Palsy and Corticobasal Degeneration Awareness Month  will benefit individuals diagnosed with the diseases, families, healthcare professionals, and communities across the country and will further bolster awareness of the diseases: Now, therefore, be it
That the Senate—
(1)
supports the designation of May 2026 as  Progressive Supranuclear Palsy and Corticobasal Degeneration Awareness Month ;
(2)
supports the goals and ideals of Progressive Supranuclear Palsy and Corticobasal Degeneration Awareness Month;
(3)
supports research on diagnosis, prevention, treatments, and cures for progressive supranuclear palsy and corticobasal degeneration;
(4)
recognizes the strength and resilience of the communities affected by progressive supranuclear palsy and corticobasal degeneration; and
(5)
commends the individuals, families, volunteers, healthcare professionals, researchers, and organizations across the country who are working to improve the lives of people living with progressive supranuclear palsy and corticobasal degeneration.